Psyence Biomedical Expands Australian Psilocybin Trial Network to Five Sites
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Psyence Biomedical ( (PBM) ).
On April 8, 2026, Psyence Biomedical announced it had expanded its Australian clinical site network from three to five locations to support its ongoing clinical activities. The new sites, Ramsay Health Care and NeuroCentrix, join existing partners in Perth and Melbourne to bolster capacity for the company’s Phase IIb trial in palliative oncology.
The multi-site Phase IIb study, run by Southern Star Research, is evaluating natural psilocybin for Adjustment Disorder in cancer patients receiving palliative care, with initial patient dosing having started in late 2025. By adding experienced hospital and specialist research partners and supplying NPX-5 from its GMP-certified facility, Psyence aims to accelerate patient recruitment, improve operational efficiency, and strengthen its position in the emerging psychedelic medicines clinical landscape.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a Nasdaq-listed biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies targeting unmet mental health needs. The company’s lead clinical asset is NPX-5, a fully GMP-compliant, pharmaceutical-grade psilocybin product manufactured via a strategic investment in PsyLabs’ GMP-controlled production facility.
Average Trading Volume: 208,455
Technical Sentiment Signal: Sell
Current Market Cap: $2.85M
See more data about PBM stock on TipRanks’ Stock Analysis page.
